Eradication rate · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes eradication rate compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes gastrointestinal adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Allergic adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events ‐ toxic reaction (short term) · patients with Helicobacter pylori infection
1 finding from 1 review
Anxiety · people with inflammatory bowel disease
2 findings from 1 review
Depression at 12 weeks · people with inflammatory bowel disease
1 finding from 1 review
Depression at 12 months · people with inflammatory bowel disease
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Pain · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of remission · people with inflammatory bowel disease
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
1 finding from 1 review
Endoscopic relapse · people with inflammatory bowel disease
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with active Crohn's disease
Antibiotic leads to lower failure to enter clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to achieve clinical response or remission · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in failure to achieve clinical response or remission compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in adverse events compared with placebo with anti‐TNF (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in withdrawal due to adverse events compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with active Crohn's disease
Antibiotic showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
Failure to achieve clinical response · Patients with active Crohn's disease
Antibiotic probably leads to lower failure to achieve clinical response compared with placebo (moderate certainty).
1 finding from 1 review